Aragon Pharma readies first cancer trial after $22M B round

Aisling Capital has joined the crew of investors backing San Diego-based start-up Aragon Pharmaceuticals, leading a $22 million Series B that will fuel its pursuit of a clinical trial on a new therapy for hormonally-driven cancer. Aragon was launched a little less than a year ago to test the commercial potential of the research work being done by Charles Sawyers, M.D., a Howard Hughes Medical Institute investigator at Memorial Sloan-Kettering Cancer Center, and Michael E. Jung, Ph.D., professor...